biotech
Syntis Bio Secures $38M for Weight Loss Pill That Mimics Gastric Bypass Surgery
Syntis Bio has raised $38M to advance its injectable-free, once-daily pill that mimics gastric bypass surgery.
23andMe Finds $256M Buyer in Regeneron After Chapter 11 Filing
Regeneron is acquiring 23andMe’s core assets for $256 million following the genetic testing company’s Chapter 11 filing.
Biolinq Lands $100M To Propel Glucose-Tracking Wearable
Biolinq raises $100M to support FDA approval of its color-changing glucose biosensor for people with Type 2 diabetes not on insulin.
Low-cost & Needle-free: Found Adds Oral Weight Loss Tablets
Found has launched affordable oral weight loss pills, but a groundbreaking drug-free solution is on the horizon from biomed company Epitomee.
Novos Founder Chris Mirabile on How to Slow One’s Biological Age
The longevity-focused biotech company founder spoke to Athletech News about best practices to increase one’s lifespan using technology.
23andMe Lays Off 40% of Staff, Dissolves Therapeutics Division
23andMe, once a biotech unicorn, is struggling to stay afloat, marred by several challenges, including the swift resignation of its board.
